Low-cost generic versions of Baraclude (entecavir) for the hepatitis B treatment have been launched by 2 more Indian companies, indicating a possible reduction in prices.
Baraclude, which contains the anti-viral drug entecavir is developed by Bristol Myers Squibb (BMS).
Zydus Cadilla and Natco Pharma are the two companies which have come out with own versions of Baraclude.
Zydus Cadila has branded the drug as Entehep while X-vir is Natco Pharma’s version. The drugs are priced Rs 82/- and Rs 75/- for 0.5 mg versions Rs 147/- for mg tablets.
Earlier, Ranbaxy had launched a generic copy of Baraclude under the brand name Entaco priced at Rs 82/- and Rs 169/- for 0.5 mg and 1 mg tablets respectively.
Meanwhile, the BMS’ Baraclude, which has been granted protection in India, costs Rs 212/- and Rs 312/- respectively.
Entecavir fights the hepatitis B virus (HBV). Entecavir is prescribed in adults where the HBV is multiplying and damaging the liver.
Entecavir, which could help reduce the amount of the virus in the blood, is taken once a day by mouth.
Entecavir does not cure HBV or stop the patients from spreading the virus to others. It is also not sure if entecavir could cut down chances of getting liver cancer or liver damage (cirrhosis), which may be caused by chronic HBV infection.